NICE again rejects Revlimid for Myelodysplastic Syndromes treatment - Celgene
In draft guidance the National Institute for Health and Care Excellence (NICE) has again refused funding for Revlimid (lenalidomide) from Celgene in patients with Myelodysplastic Syndromes characterised by a chromosomal abnormality called a deletion 5q cytogenetic abnormality. This rejection is because while clinical experts told the committee that Revlimid is an effective therapy, the data provided by Celgene "showed uncertainty about whether lenalidomide actually extended lives", although NICE did concede that a survival benefit was plausible.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.